-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
During -X- _ O
pandemics -X- _ O
, -X- _ O
health -X- _ O
authorities -X- _ O
may -X- _ O
be -X- _ O
uncertain -X- _ O
about -X- _ O
the -X- _ O
spread -X- _ O
and -X- _ O
severity -X- _ O
of -X- _ O
the -X- _ O
disease -X- _ O
and -X- _ O
the -X- _ O
effectiveness -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
available -X- _ O
interventions. -X- _ O
This -X- _ O
was -X- _ O
the -X- _ O
case -X- _ O
during -X- _ O
the -X- _ O
swine -X- _ B-Patient
flu -X- _ I-Patient
( -X- _ I-Patient
H1N1 -X- _ I-Patient
) -X- _ I-Patient
pandemic -X- _ I-Patient
of -X- _ I-Patient
2009–2010 -X- _ I-Patient
, -X- _ O
and -X- _ O
governments -X- _ O
were -X- _ O
forced -X- _ O
to -X- _ O
make -X- _ O
decisions -X- _ O
despite -X- _ O
these -X- _ O
uncertainties. -X- _ O
While -X- _ O
many -X- _ O
countries -X- _ O
chose -X- _ O
to -X- _ O
implement -X- _ O
wide -X- _ B-Intervention
scale -X- _ I-Intervention
vaccination -X- _ I-Intervention
programmes -X- _ I-Intervention
, -X- _ O
few -X- _ O
accomplished -X- _ O
their -X- _ O
vaccination -X- _ O
goals. -X- _ O
Many -X- _ O
research -X- _ O
studies -X- _ O
aiming -X- _ O
to -X- _ O
explore -X- _ O
barriers -X- _ O
and -X- _ O
facilitators -X- _ O
to -X- _ O
vaccine -X- _ O
uptake -X- _ O
have -X- _ O
been -X- _ O
conducted -X- _ O
in -X- _ O
the -X- _ O
aftermath -X- _ O
of -X- _ O
the -X- _ O
pandemic -X- _ O
, -X- _ O
including -X- _ O
several -X- _ O
qualitative -X- _ O
studies. -X- _ O
AIMS -X- _ O
: -X- _ O
1. -X- _ O
To -X- _ O
explore -X- _ O
public -X- _ O
attitudes -X- _ O
to -X- _ O
the -X- _ O
swine -X- _ B-Intervention
flu -X- _ I-Intervention
vaccine -X- _ I-Intervention
in -X- _ O
different -X- _ O
countries -X- _ O
through -X- _ O
a -X- _ O
review -X- _ O
of -X- _ O
qualitative -X- _ O
primary -X- _ O
studies. -X- _ O
2. -X- _ O
To -X- _ O
describe -X- _ O
and -X- _ O
discuss -X- _ O
the -X- _ O
implications -X- _ O
drawn -X- _ O
by -X- _ O
the -X- _ O
primary -X- _ O
study -X- _ O
authors. -X- _ O
METHODS -X- _ O
: -X- _ O
Systematic -X- _ O
review -X- _ O
of -X- _ O
qualitative -X- _ O
research -X- _ O
studies -X- _ O
, -X- _ O
using -X- _ O
a -X- _ O
broadly -X- _ O
comparative -X- _ O
cross -X- _ O
case-study -X- _ O
approach. -X- _ O
Study -X- _ O
quality -X- _ O
was -X- _ O
appraised -X- _ O
using -X- _ O
an -X- _ O
adaptation -X- _ O
of -X- _ O
the -X- _ O
Critical -X- _ O
Appraisal -X- _ O
Skills -X- _ O
Programme -X- _ O
( -X- _ O
CASP -X- _ O
) -X- _ O
quality -X- _ O
assessment -X- _ O
tool. -X- _ O
RESULTS -X- _ O
: -X- _ O
The -X- _ O
review -X- _ O
indicates -X- _ O
that -X- _ O
the -X- _ O
public -X- _ O
had -X- _ O
varying -X- _ O
opinions -X- _ O
about -X- _ O
disease -X- _ O
risk -X- _ O
and -X- _ O
prevalence -X- _ O
and -X- _ O
had -X- _ O
concerns -X- _ O
about -X- _ O
vaccine -X- _ O
safety. -X- _ O
Most -X- _ O
primary -X- _ O
study -X- _ O
authors -X- _ O
concluded -X- _ O
that -X- _ O
participants -X- _ O
were -X- _ O
uninformed -X- _ O
, -X- _ O
and -X- _ O
that -X- _ O
more -X- _ O
information -X- _ O
about -X- _ O
the -X- _ O
disease -X- _ O
and -X- _ O
the -X- _ O
vaccine -X- _ O
would -X- _ O
have -X- _ O
led -X- _ O
to -X- _ O
an -X- _ O
increase -X- _ O
in -X- _ O
vaccine -X- _ O
uptake. -X- _ O
We -X- _ O
find -X- _ O
these -X- _ O
conclusions -X- _ O
problematic. -X- _ O
We -X- _ O
suggest -X- _ O
instead -X- _ O
that -X- _ O
people’s -X- _ O
questions -X- _ O
and -X- _ O
concerns -X- _ O
were -X- _ O
legitimate -X- _ O
given -X- _ O
the -X- _ O
uncertainties -X- _ O
of -X- _ O
the -X- _ O
situation -X- _ O
at -X- _ O
the -X- _ O
time -X- _ O
and -X- _ O
the -X- _ O
fact -X- _ O
that -X- _ O
the -X- _ O
authorities -X- _ O
did -X- _ O
not -X- _ O
have -X- _ O
the -X- _ O
necessary -X- _ O
information -X- _ O
to -X- _ O
convince -X- _ O
the -X- _ O
public. -X- _ O
Our -X- _ O
quality -X- _ O
assessment -X- _ O
of -X- _ O
the -X- _ O
included -X- _ O
studies -X- _ O
points -X- _ O
to -X- _ O
a -X- _ O
lack -X- _ O
of -X- _ O
reflexivity -X- _ O
and -X- _ O
a -X- _ O
lack -X- _ O
of -X- _ O
information -X- _ O
about -X- _ O
study -X- _ O
context. -X- _ O
We -X- _ O
suggest -X- _ O
that -X- _ O
these -X- _ O
study -X- _ O
weaknesses -X- _ O
are -X- _ O
tied -X- _ O
to -X- _ O
primary -X- _ O
study -X- _ O
authors’ -X- _ O
lack -X- _ O
of -X- _ O
acknowledgement -X- _ O
of -X- _ O
the -X- _ O
uncertainties -X- _ O
surrounding -X- _ O
the -X- _ O
disease -X- _ O
and -X- _ O
the -X- _ O
vaccine. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
While -X- _ B-Outcome
primary -X- _ I-Outcome
study -X- _ I-Outcome
authors -X- _ I-Outcome
suggest -X- _ I-Outcome
that -X- _ I-Outcome
authorities -X- _ I-Outcome
could -X- _ I-Outcome
increase -X- _ I-Outcome
vaccine -X- _ I-Outcome
uptake -X- _ I-Outcome
through -X- _ I-Outcome
increased -X- _ I-Outcome
information -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
suggest -X- _ I-Outcome
instead -X- _ I-Outcome
that -X- _ I-Outcome
health -X- _ I-Outcome
authorities -X- _ I-Outcome
should -X- _ I-Outcome
be -X- _ I-Outcome
more -X- _ I-Outcome
transparent -X- _ I-Outcome
in -X- _ I-Outcome
their -X- _ I-Outcome
information -X- _ I-Outcome
and -X- _ I-Outcome
decision-making -X- _ I-Outcome
processes -X- _ I-Outcome
in -X- _ I-Outcome
future -X- _ I-Outcome
pandemic -X- _ I-Outcome
situations. -X- _ I-Outcome
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
doi:10.1186 -X- _ O
/ -X- _ O
s12913-016-1466-7 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

